当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
32期
143-144
,共2页
时淑珍%付静%董笑洋
時淑珍%付靜%董笑洋
시숙진%부정%동소양
雷替曲塞%奥沙利铂%晚期结直肠癌
雷替麯塞%奧沙利鉑%晚期結直腸癌
뢰체곡새%오사리박%만기결직장암
Raltitrexed%Oxaliplatin%Advanced colorectal cancer
目的:比较雷替曲塞或5-氟尿嘧啶(5-Fu)/亚叶酸钙(CF)联合奥沙利铂治疗晚期结直肠癌的有效性和安全性。方法经病理组织学确诊的晚期结直肠癌患者40例,随机分入治疗组和对照组。治疗组:雷替曲塞3 mg/m 2 d 1;奥沙利铂130 mg/m 2 d 1。对照组:亚叶酸钙200 mg/m 2 d 1-5;氟尿嘧啶375 mg/m 2 d 1-5;奥沙利铂130 mg/m 2 d 1。两方案均以21 d为1周期,每2个周期评价疗效及不良反应。结果治疗组和对照组的有效率分别为45.0%(9/20)和15.0%(3/20),两组间比较差异有统计学意义(P<0.05)。临床获益率比较,两组分别是80.0%(16/20)和50.0%(10/20),两组间比较差异有统计学意义(P<0.05)。治疗组转氨酶升高率高于对照组,对照组呕吐发生率高于治疗组,但均无明显差异(P>0.05)。结论雷替曲塞联合奥沙利铂治疗晚期结直肠癌安全、有效。
目的:比較雷替麯塞或5-氟尿嘧啶(5-Fu)/亞葉痠鈣(CF)聯閤奧沙利鉑治療晚期結直腸癌的有效性和安全性。方法經病理組織學確診的晚期結直腸癌患者40例,隨機分入治療組和對照組。治療組:雷替麯塞3 mg/m 2 d 1;奧沙利鉑130 mg/m 2 d 1。對照組:亞葉痠鈣200 mg/m 2 d 1-5;氟尿嘧啶375 mg/m 2 d 1-5;奧沙利鉑130 mg/m 2 d 1。兩方案均以21 d為1週期,每2箇週期評價療效及不良反應。結果治療組和對照組的有效率分彆為45.0%(9/20)和15.0%(3/20),兩組間比較差異有統計學意義(P<0.05)。臨床穫益率比較,兩組分彆是80.0%(16/20)和50.0%(10/20),兩組間比較差異有統計學意義(P<0.05)。治療組轉氨酶升高率高于對照組,對照組嘔吐髮生率高于治療組,但均無明顯差異(P>0.05)。結論雷替麯塞聯閤奧沙利鉑治療晚期結直腸癌安全、有效。
목적:비교뢰체곡새혹5-불뇨밀정(5-Fu)/아협산개(CF)연합오사리박치료만기결직장암적유효성화안전성。방법경병리조직학학진적만기결직장암환자40례,수궤분입치료조화대조조。치료조:뢰체곡새3 mg/m 2 d 1;오사리박130 mg/m 2 d 1。대조조:아협산개200 mg/m 2 d 1-5;불뇨밀정375 mg/m 2 d 1-5;오사리박130 mg/m 2 d 1。량방안균이21 d위1주기,매2개주기평개료효급불량반응。결과치료조화대조조적유효솔분별위45.0%(9/20)화15.0%(3/20),량조간비교차이유통계학의의(P<0.05)。림상획익솔비교,량조분별시80.0%(16/20)화50.0%(10/20),량조간비교차이유통계학의의(P<0.05)。치료조전안매승고솔고우대조조,대조조구토발생솔고우치료조,단균무명현차이(P>0.05)。결론뢰체곡새연합오사리박치료만기결직장암안전、유효。
Objective To assess the efficacy and safety of oxaliplatin plus raltitrexed with oxaliplatin plus fluorouracil and leucovorin for advanced colorectal cancer. Methods 40 cases of advanced colorectal cancer confirmed by pathology were randomly assigned to treatment group and control group. Treatment group:raltitrexed 3 mg/m 2d 1;oxaliplatin 130 mg/m 2d 1. Control group:leucovorin 200 mg/m 2d 1-5;fluorouracil 375 mg/m 2 d 1-5;oxaliplatin 130 mg/m 2 d 1. The two regiments were 21 days as a cycle. The efficacy and safety were evaluated after two cycles. Results In the treatment group, the effective rate 45.0%(9/20) and clinical beneficial rate 80.0%(16/20) were significantly higher than those of the control group respectively (P<0.05).The elevated transaminase enzymes in the treatment group was higher than that in the control group and the vomiting was lower than that in the control group. There was no significant difference between the two groups(P>0.05). Conclusion Raltitrexed combined with oxaliplatin is safe and effective in the treatment of advanced colorectal cancer.